c19early.org COVID-19 treatment researchCOVID-19 treatments

Kintor Pharma's Proxalutamide Demonstrated Reduction in Hospitalization/Mortality for Patients with Mild to Moderate COVID-19 in Phase III MRCT Study

Kintor, Press Release, NCT04870606, Apr 2022
Early treatmentRCT · 730 patients · USA · Mar 2021 – Apr 2022
Proxalutamide for COVID-19
Kintor Press Release · April 2022 · NCT04870606
Improved viral clearance with antiandrogens
p = 0.0001

Antiandrogens for COVID-19

7th treatment shown to reduce risk in September 2020, now with p = 0.000000056 from 49 studies.
Lower risk for mortality, ventilation, ICU, hospitalization, recovery, cases, and viral clearance.

No treatment is 100% effective.
Protocols combine treatments.

6,700+ studies · 220+ treatments

c19early.org
Meta-analysis
RCT 733 outpatients, 99% in the USA, showing lower hospitalization/death, and significantly reduced viral load with proxalutamide treatment. The viral clearance result is from Ma et al.
Standard of Care (SOC) for COVID-19 in the study country, the USA, is very poor with very low average efficacy for approved treatments2. Only expensive, high-profit treatments were approved for early treatment. Low-cost treatments were excluded, reducing the probability of early treatment due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.
Important missing comments or errors? Let us know.
OutcomeImprovementEffect · pTreatmentControl
risk of death 66.7% lower · RR 0.33 · p = 1.00 66.7% lowerRR 0.33p = 1.00 0 of 365 (0.0%) 1 of 365 (0.3%) treatment 0 of 365 (0.0%), control 1 of 365 (0.3%)1+ days of treatment, group sizes approximatedNNT 365continuity correction due to zero events
risk of hospitalization 50.0% lower · RR 0.50 · p = 0.38 50.0% lowerRR 0.50p = 0.38 4 of 365 (1.1%) 8 of 365 (2.2%) treatment 4 of 365 (1.1%), control 8 of 365 (2.2%)1+ days of treatment, group sizes approximatedNNT 91
risk of death 66.6% lower · RR 0.33 · p = 1.00 66.6% lowerRR 0.33p = 1.00 0 of 360 (0.0%) 1 of 361 (0.3%) treatment 0 of 360 (0.0%), control 1 of 361 (0.3%)>1 day of treatment, group sizes approximatedNNT 361continuity correction due to zero events
risk of hospitalization 71.3% lower · RR 0.29 · p = 0.18 71.3% lowerRR 0.29p = 0.18 2 of 360 (0.6%) 7 of 361 (1.9%) treatment 2 of 360 (0.6%), control 7 of 361 (1.9%)>1 day of treatment, group sizes approximatedNNT 72
risk of death 66.6% lower · RR 0.33 · p = 1.00 66.6% lowerRR 0.33p = 1.00 0 of 346 (0.0%) 1 of 347 (0.3%) treatment 0 of 346 (0.0%), control 1 of 347 (0.3%)>7 days of treatment, group sizes approximatedNNT 347continuity correction due to zero events
risk of hospitalization 92.3% lower · RR 0.08 · p = 0.03* 92.3% lowerRR 0.08p = 0.03* 0 of 346 (0.0%) 6 of 347 (1.7%) treatment 0 of 346 (0.0%), control 6 of 347 (1.7%)>7 days of treatment, group sizes approximatedNNT 58continuity correction due to zero events
risk of no viral clearance 73.9% lower · RR 0.26 · p < 0.0001*** 73.9% lowerRR 0.26p < 0.0001*** 365 365 treatment 365, control 365group sizes approximatedday 7

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates. * p < 0.05   *** p < 0.001

Kintor et al., 5 Apr 2022, Double Blind Randomized Controlled Trial, placebo-controlled, USA, preprint, 1 author, study period 5 March, 2021 - 1 April, 2022, trial NCT04870606 (history).
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2026 USA Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Argentina Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Nigeria Taiwan Fiji Zambia Bosnia-Herzegovina Jordan Georgia Switzerland Dominican Republic Bolivia Côte d'Ivoire Eritrea Togo Bulgaria Greece Slovakia Iceland New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel Haiti North Macedonia Hong Kong Qatar Panama Serbia USA favored high-profit treatments.The average efficacy of treatments was very low.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2026 USA Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Argentina Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Taiwan Fiji Zambia Jordan Georgia Switzerland Dominican Rep. Bolivia Côte d'Ivoire Eritrea Togo Sri Lanka Bulgaria Greece Slovakia New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel North Macedonia Hong Kong Qatar Panama Serbia USA favored high-profit treatments.The average efficacy was very low.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%